Try our Advanced Search for more refined results
Life Sciences
-
January 12, 2026
The Curious, Very Long Delay In A Pioneering Drug Prices Suit
When Merck & Co. launched a fiery challenge to Medicare's landmark drug price negotiations, it blazed a trail for many similar suits. But 31 months later, the challenge is stalled where it started as Merck begs for a ruling, other suits speed along the path it created and huge costs now seem unavoidable.
-
January 12, 2026
Del. Jurist Cites 'Troubling' Questions In Cashout Suit
A Delaware vice chancellor described as "troubling" on Monday unsettled questions in a stockholders' amended suit alleging an unfair recapitalization that allegedly forced out Bioventix Inc. common stockholders for a penny per share ahead of a new financing, asking how much discovery had been taken before filing of the complaint.
-
January 12, 2026
Terumo Plaintiff Settles, Drops Cancer Case Before Trial
One of the two plaintiffs set to take their case to trial this month against Terumo BCT Inc. accusing the company of causing their cancer reached a stipulation to dismiss his case with prejudice Friday, according to court records.
-
January 12, 2026
Del. Court Blocks Presuit Damages On Agilent Patent
A Delaware federal court ruled that laboratory equipment company Agilent Technologies couldn't collect damages for any alleged infringement of one of its patents prior to the filing of its intellectual property lawsuit against biotechnology business Axion BioSystems.
-
January 12, 2026
Feds To Drop Appeal In 340B Rebate Pilot Challenge
The U.S. Department of Health and Human Services on Monday suggested it will end its appeal of a First Circuit order temporarily blocking it from instituting a rebate program that would change how the agency distributes payments in the federal 340B drug discount program that provides medications at reduced costs to low-income Americans.
-
January 12, 2026
Sidley-Led Smith & Nephew Inks $450M Orthopaedics Deal
Sidley Austin-advised Smith & Nephew said Monday it will acquire Gunderson Dettmer-led U.S. sports medicine company Integrity Orthopaedics and its Tendon Seam rotator cuff repair technology in a deal valued at up to $450 million.
-
January 12, 2026
Medicine Biz Mirador Wraps $250M Funding Round
San Diego-based clinical-stage precision medicine company Mirador Therapeutics Inc. announced Monday that it closed its Series B funding round with $250 million of investor commitments, bringing the company's total capital raised since its March 2024 launch to more than $650 million.
-
January 12, 2026
Justices Want SG Input On Arthritis Drug Competition Fight
The U.S. Supreme Court on Monday asked the Trump administration to weigh in on whether state unfair competition claims should be used to block a competitor from selling compounded versions of drugs in certain states.
-
January 12, 2026
No High Court Review For California Opioid 'Nuisance' Suit
The U.S. Supreme Court on Monday said it would not weigh in on a circuit court decision that a California public nuisance lawsuit against pharmacy benefit managers over their opioid-dispensing practices belongs in state court.
-
January 12, 2026
Justices Won't Weigh Collective Cert. Process In Eli Lilly Case
The U.S. Supreme Court declined on Monday to review whether courts should stick with a long-standing two-step analysis for certifying collective actions in an age discrimination case against Eli Lilly and Co. that could have affected wage and hour litigation.
-
January 09, 2026
Mylan, Aurobindo Must Face Generic Drug Price-Fixing Claims
A Connecticut federal judge on Friday refused to hand a quick win to Mylan Pharmaceuticals and Aurobindo Pharma USA in sprawling antitrust litigation against 26 total pharmaceutical companies, ruling that a coalition of states has enough evidence to raise a genuine dispute about whether the companies conspired to fix drug prices.
-
January 09, 2026
Squires Sets Precedent, Guidance On Discretionary Denials
U.S. Patent and Trademark Office Director John Squires on Friday designated four decisions on discretionary denials at the Patent Trial and Appeal Board precedential and another nine informative.
-
January 09, 2026
Biopharma Co. Secures D&O Coverage For Shareholder Suit
A biopharmaceutical company is entitled to coverage for a suit alleging its board breached fiduciary duties under a pair of primary and excess directors and officers policies, a Delaware state court ruled, saying the suit is "meaningfully linked" to a previously noticed demand for books and records.
-
January 09, 2026
Veterinary Group Says DOJ Accreditation Points Irrelevant
The American Veterinary Medical Association has told a Tennessee federal court that the government's concerns about professional groups are irrelevant to a veterinary school's antitrust case challenging the association's accreditation requirements.
-
January 09, 2026
Judge Denies 'Fatally Untimely' Bid For New Poaching Trial
A Boston federal judge has denied what she called a "fatally untimely" motion for a new trial after a jury handed Cynosure LLC a $25 million verdict against two former employees who the company said caused other employees to breach their noncompete and nonsolicitation agreements.
-
January 09, 2026
Judge Blocks Edwards' $945M Heart Valve Deal
A D.C. federal judge issued an order on Friday preventing Edwards Lifesciences Corp. from moving ahead with its planned $945 million deal for JenaValve Technology Inc., torpedoing the merger challenged by the Federal Trade Commission.
-
January 09, 2026
4 Argument Sessions That Benefits Attys Should Watch In Jan.
The U.S. Supreme Court will zero in on the methodology for assessing liability for pulling out of a multi-employer pension fund, and the circuit courts will hear bids to revive suits over alleged 401(k) mismanagement and deferred compensation. Here, Law360 looks at a quartet of oral arguments coming up in January.
-
January 09, 2026
How New Judges Can Quell Patent Litigation Fears
Patent litigation has a reputation for being particularly complex due to its technical content, which can be intimidating for litigants, attorneys and judges alike. In the first of a two-part series, several judges in the trenches of patent law spoke with Law360 about how new judges can make patent litigation less overwhelming.
-
January 09, 2026
Ex-Prosecutor OK For Drug Pricing MDL, Special Master Says
Former Connecticut Assistant Attorney General Joseph Nielsen and his law firm, Lowey Dannenberg PC, should not be disqualified from representing insurers in multidistrict litigation over generic drug price-fixing because he did not have any special knowledge that the states suing drugmakers hadn't already shared with the private plaintiffs, according to a special master's report and recommendation.
-
January 09, 2026
Biotech AirNexis Wraps Funding Round With $200M Raised
Clinical stage biotech firm AirNexis, advised by Fenwick & West LLP, on Friday announced that it wrapped its Series A funding round with $200 million in tow, which will be used to fund the global clinical development of a therapy used for chronic obstructive pulmonary disease.
-
January 09, 2026
NC Biz Court Bulletin: Trade Secrets Row, A Patient Data Deal
The North Carolina Business Court closed out the year by tossing a trade secrets fight brought by a corrugated packing manufacturer against its onetime star salesman and signing off on a $2.45 million settlement ending claims a healthcare system sold patients' data to Meta.
-
January 09, 2026
IDEXX Software Defect Blamed For At Least 40 Dog Deaths
Two Los Angeles-based veterinary clinics say pet healthcare diagnostics company Idexx Distribution Inc. fraudulently concealed a software algorithm defect that allegedly led to at least 40 dogs dying and hundreds of animals getting sick or missing treatment due to false diagnostic testing, according to a new lawsuit in California state court.
-
January 09, 2026
Paul Hastings-Led Oncology Firm Prices Upsized $318M IPO
Boston-based biotech firm Atkis Oncology began trading publicly Friday after raising roughly $318.6 million in its upsized initial public offering, marking the first sizable IPO of 2026.
-
January 08, 2026
Walgreens Gets $392K Sanction Against Blue Cross Insurers
A Chicago federal judge on Thursday ordered a host of Blue Cross Blue Shield insurers to pay Walgreens more than $392,000 in attorney fees and expenses for discovery misconduct in their suit that accuses the drugstore company of fraudulently overcharging for prescription drugs.
-
January 08, 2026
Apple Beats Antitrust Suit Over Heart Rate Data At 9th Circ.
A Ninth Circuit panel affirmed Apple's win Thursday against startup AliveCor Inc.'s antitrust claims alleging it illegally blocked third-party access to Apple Watch medical data to create rival software, finding that Apple has no "duty to deal" with AliveCor and therefore the startup's claims fail as a matter of law.
Expert Analysis
-
Data Undermines USPTO's 'Settled Expectations' Doctrine
An analysis of inter partes review proceedings filed since 2012 appears to refute the U.S. Patent and Trademark Office's recent stance that patent owners develop a strong settled expectation that their patents will not be challenged after being in force for six years, say Jonathan DeFosse and Samuel Smith at Sheppard Mullin, and Kenzo Kasai at NGB Corp.
-
Advice For 1st-Gen Lawyers Entering The Legal Profession
Nikki Hurtado at The Ferraro Law Firm tells her story of being a first-generation lawyer and how others who begin their professional journeys without the benefit of playbooks handed down by relatives can turn this disadvantage into their greatest strength.
-
High Court E-Cig Ruling Opens Door For FDA Challenges
There will likely be more challenges to marketing denial orders brought before the Fifth Circuit following the Supreme Court's recent ruling in U.S. Food and Drug Administration v. R.J. Reynolds Vapor Co., where litigants have generally had greater success, say attorneys at Troutman Pepper.
-
Fed. Circ. In July: Instability In IPR Requirements
The Federal Circuit's decision in Shockwave v. Cardiovascular last month provided an important, albeit short-lived, clarification to the type of evidence that can be used in an inter partes review challenge, say attorneys at Knobbe Martens.
-
Structuring Noncompetes In License And Collaboration Deals
As companies grappling with coming patent cliffs look to mergers and acquisitions to compensate, contracting parties assessing biopharma license and collaboration agreements should prepare to agree on noncompetes that ensure the parties' respective objectives are met and that their incentives are aligned, both under their collaboration and beyond, says Jeff Jay at Freshfields.
-
Series
Coaching Cheerleading Makes Me A Better Lawyer
At first glance, cheerleading and litigation may seem like worlds apart, but both require precision, adaptability, leadership and the ability to stay composed under pressure — all of which have sharpened how I approach my work in the emotionally complex world of mass torts and personal injury, says Rashanda Bruce at Robins Kaplan.
-
7 Ways To Fetch Patents In The World Of Working Animals
Though developers rarely file patents related to working animals, and animal training techniques are generally considered unpatentable, certain aspects of training and developing animals may be ripe for patent protection, say Matthew Avery at Baker Botts, Makenzi Galvan at Perkins Coie and Lute Yang at Orrick.
-
9th Circ.'s Kickback Ruling Strengthens A Prosecutorial Tool
The Ninth Circuit's decision last month in U.S. v. Schena, interpreting the Eliminating Kickbacks in Recovery Act to prohibit kickback conduct between the principal and individuals who do not directly interact with patients, serves as a wake-up call to the booming clinical laboratory testing industry, say attorneys at Kendall Brill.
-
Series
Law School's Missed Lessons: How To Make A Deal
Preparing lawyers for the nuances of a transactional practice is not a strong suit for most law schools, but, in practice, there are six principles that can help young M&A lawyers become seasoned, trusted deal advisers, says Chuck Morton at Venable.
-
From Clerkship To Law Firm: 5 Transition Tips For Associates
Excerpt from Practical Guidance
Transitioning from a judicial clerkship to an associate position at a law firm may seem daunting, but by using knowledge gained while clerking, being mindful of key differences and taking advantage of professional development opportunities, these attorneys can flourish in private practice, say attorneys at Lowenstein Sandler.
-
9th Circ.'s Trade Secrets Ruling Is A Win For DTSA Plaintiffs
The Ninth Circuit's recent decision in Quintara v. Ruifeng shifts the balance in federal trade secret litigation toward a more flexible, discovery-driven process, meaning that plaintiffs may be more likely to pursue claims under the Defend Trade Secrets Act, and early motions to strike or dismiss will face steep odds, say attorneys at Cooley.
-
Associates Can Earn Credibility By Investing In Relationships
As the class of 2025 prepares to join law firms this fall, new associates must adapt to office dynamics and establish credible reputations — which require quiet, consistent relationship-building skills as much as legal acumen, says Kyle Forges at Bast Amron.
-
Puzzling Out When Similar Insurance Claims Are Related
A recent decision in Virginia federal court shows that more than identical allegations of negligent business practices across two lawsuits may be necessary to satisfy the strict definition of relatedness under claims-made liability insurance policies, say attorneys at Hunton.
-
A Shifting Trend In FDA Form 483 Disclosure Obligations
A New York federal court's Checkpoint Therapeutics decision extends a recent streak of dismissals of securities class actions alleging that pharmaceutical companies failed to disclose U.S. Food and Drug Administration Form 483 inspection reports, providing critical guidance for companies during the FDA approval process, say attorneys at Alston & Bird.
-
Trending At The PTAB: IPR Memo And Its Fed. Circ. Backdrop
There are new rules for when and how evidence other than patents or printed publications can be considered in inter partes reviews, and while this change is intended to reflect current Federal Circuit precedent, the U.S. Patent and Trademark Office's memo seems to acknowledge tension with last month's Shockwave decision, say attorneys at Finnegan.